The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Saved in:
Bibliographic Details
Published inFuture oncology (London, England) Vol. 19; no. 11; pp. 737 - 738
Main Authors Karmali, Reem, St-Pierre, Frederique, Gordon, Leo I
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.04.2023
Subjects
aggressive non-Hodgkin lymphoma
diffuse large B-cell lymphoma
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Non-Hodgkin - pathology
mivavotinib
SYK inhibitor
Syk Kinase
TAK-659
diffuse large B-cell lymphoma
mivavotinib
SYK inhibitor
aggressive non-Hodgkin lymphoma
TAK-659
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2022-1280